Prognostic significance of Bacillus Calmette-Guérin failure classification in non-muscle-invasive bladder cancer

BJU International

Volumn 110, Issue 6B, 2012, Pages

  Shirakawa, Hiroshi ^a   Kikuchi, Eiji ^a   Tanaka, Nobuyuki ^a   Matsumoto, Kazuhiro ^a   Miyajima, Akira ^a   Nakamura, So ^b   Oya, Mototsugu ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SAISEIKAI CENTRAL HOSPITAL   (Japan)

Author keywords

BCG failure; BCG refractory; non muscle invasive bladder cancer; stage progression

Indexed keywords

BCG VACCINE;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RELAPSE; CANCER STAGING; CLINICAL FEATURE; CYSTECTOMY; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; INDIVIDUALIZATION; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MEDICAL RECORD REVIEW; MULTIVARIATE ANALYSIS; NON MUSCLE INVASIVE BLADDER CANCER; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; TRANSURETHRAL RESECTION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; AGED, 80 AND OVER; BCG VACCINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT FAILURE; URINARY BLADDER NEOPLASMS;

EID: 84865484338     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10894.x     Document Type: Article

References (17)

1. Babjuk M, Oosterlinck W, Sylvester R, et al,. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 2011; 59: 997-1008
2. Witjes JA, Caris CT, Mungan NA, Debruyne FM, Witjes WP,. Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer. J Urol 1998; 160: 1668-71
3. Witjes JA, Meijden AP, Collette L, et al,. Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille Calmette-Guerin-RIVM and mitomycin C in superficial bladder cancer. EORTC GU Group and the Dutch South East Cooperative Urological Group. European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group. Urology 1998; 52: 403-10
4. Sylvester RJ, Brausi MA, Kirkels WJ, et al,. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guerin, and bacillus Calmette-Guerin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol 2010; 57: 766-73
5. Fernandez-Gomez J, Solsona E, Unda M, et al,. Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials. Eur Urol 2008; 53: 992-1001
6. Pansadoro V, Emiliozzi P, de Paula F, et al,. Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guerin: 18-year experience. Urology 2002; 59: 227-31 (Pubitemid 34134520)
7. Hurle R, Losa A, Manzetti A, Lembo A,. Intravesical bacille Calmette-Guerin in stage T1 grade 3 bladder cancer therapy: a 7-year follow-up. Urology 1999; 54: 258-63 (Pubitemid 29367248)
8. Tanaka N, Kikuchi E, Matsumoto K, et al,. Frequency of tumor recurrence: a strong predictor of stage progression in initially diagnosed nonmuscle invasive bladder cancer. J Urol 2011; 185: 450-5
9. Klein EA, Rogatko A, Herr HW,. Management of local bacillus Calmette-Guérin failures in superficial bladder cancer. J Urol 1992; 147: 601-5
10. Glashan RW,. A randomized controlled study of intravesical alpha-2b-interferon in carcinoma in situ of the bladder. J Urol 1990; 144: 658-61 (Pubitemid 20296718)
11. Sarosdy MF, Manyak MJ, Sagalowsky AI, et al,. Oral bropirimine immunotherapy of bladder carcinoma in situ after prior intravesical bacille Calmette-Guérin. Urology 1998; 51: 226-31 (Pubitemid 28093172)
12. Dalbagni G, Russo P, Bochner B, et al,. Phase II trial of intravesical gemcitabine in bacille Calmette-Guerin-refractory transitional cell carcinoma of the bladder. J Clin Oncol 2006; 24: 2729-34 (Pubitemid 46630569)
13. Herr HW, Dalbagni G,. Defining bacillus Calmette-Guérin refractory superficial bladder tumors. J Urol 2003; 169: 1706-8 (Pubitemid 36443476)
14. Nieder AM, Brausi M, Lamm D, et al,. Management of stage T1 tumors of the bladder: International Consensus Panel. Urology 2005; 66: 108-25 (Pubitemid 43049612)
15. Lerner SP, Tangen CM, Sucharew H, Wood D, Crawford ED,. Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer. Urol Oncol 2009; 27: 155-9
16. Herr HW, Badalament RA, Amato DA, et al,. Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression. J Urol 1989; 141: 22-9 (Pubitemid 19028816)
17. Andius P, Holmäng S,. Bacillus Calmette-Guérin therapy in stage Ta/T1 bladder cancer: prognostic factors for time to recurrence and progression. BJU Int 2004; 93: 980-4 (Pubitemid 38758618)